Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorecivivint in knee osteoarthritis
NCT03928184Phase 3Completed
- Sponsor
- Biosplice Therapeutics
- Start
- May 2019
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing Lorecivivint 0.07 mg with Placebo (2 arms). Primary endpoint: Pain Numeric Rating Scale at 12 weeks. Started May 2019; status: completed.
02
Drugs
lorecivivint
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03928184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928184.